UK-based Alchemab Therapeutics, a biopharma seeking to identify and develop naturally occurring therapeutic antibodies from ...

DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the HEALEY trial.

Alchemab Therapeutics (Alchemab), a biopharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies from resilient individuals, today announces it has entered a ...

The UK biopharma company Alchemab Therapeutics announced today that it has joined forces with Eli Lilly to discover, develop, ...

Alchemab Therapeutics, a biopharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies ...

The voice of Israeli journalist Moshe Nussbaum has been revived using artificial intelligence after he was diagnosed with ALS.

A research team has discovered intricate molecular mechanisms driving the RNA processing defects that lead to Huntington's disease and link HD with other neurodegenerative disorders such as ...

However, as it became increasingly difficult for Nussbaum to speak, and to be understood, his interviews became less frequent ...

The following is a summary of “Education moderates the association between motor involvement and executive status in ALS,” published in the December 2024 issue of Neurology by Aiello et al.

Neurodegenerative diseases pose a serious threat to public health, with an increasing impact among the elderly population.

For the primary analysis, a total of 186 participants who received DNL343 treatment were compared to 139 participants who ...